Prognostic implications of overt congestion in heart failure with preserved ejection fraction and the interaction with spironolactone: Insights from TOPCAT

Chin Med J (Engl). 2024 May 20;137(10):1249-1251. doi: 10.1097/CM9.0000000000002870. Epub 2023 Oct 10.
No abstract available

MeSH terms

  • Heart Failure* / drug therapy
  • Humans
  • Male
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Prognosis
  • Spironolactone* / therapeutic use
  • Stroke Volume* / drug effects
  • Stroke Volume* / physiology